Application-Assisted Weight Management in Endometrial Cancer Fertility Preservation
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age18-60
SponsorPeking University People's Hospital
About this trial
This study is a single-center, prospective, randomized controlled trial targeting endometrial cancer (EC) patients undergoing fertility-sparing treatment at Peking University People's Hospital from March 2025 to March 2027. The aim is to evaluate the efficacy of an intelligent mobile application (APP) based on the Adaptive Behavioral Intervention (ABI) framework in weight management for obese or overweight endometrial cancer patients receiving fertility preservation therapy. Additionally, the study seeks to explore its potential advantages in improving body mass index (BMI), tumor regression, and glucose and lipid metabolism profiles.
Eligibility criteria
Qualifiers
BMI ≥ 25 kg/m²
Histologically confirmed endometrial carcinoma via diagnostic curettage, hysteroscopic endometrial biopsy, or needle biopsy
Clinical FIGO 2009 stage IA disease: No evidence of extrauterine metastasis or myometrial invasion on imaging (MRI/CT)
ECOG < 2
Disqualifiers
High-grade or p53-mutated (p53mut) endometrial cancer
Currently using weight-loss medications
Pregnant or breastfeeding
Presence of communication barriers that prevent understanding and participation in the informed consent process
Trial design
Treatments tested in this trial
- DEAR weight management
- Standardized discharge care plan and follow-up schedule
- Implementation of the weight management mobile health application
- Implementation of the weight management mobile health application + Enhance the regular interaction, feedback, and supervision mechanism between medical teams and apps
Treatment groups
106 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov